These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment. Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310 [TBL] [Abstract][Full Text] [Related]
5. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837 [TBL] [Abstract][Full Text] [Related]
6. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment. Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242 [TBL] [Abstract][Full Text] [Related]
8. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations. Fischer PA; Baas H Eur Neurol; 1987; 27 Suppl 1():81-7. PubMed ID: 3322840 [TBL] [Abstract][Full Text] [Related]
9. Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study. Nordera GP; Lorizio A; Lion P; Durisotti C; D'Andrea G; Ferro-Milone F Eur Neurol; 1987; 27 Suppl 1():76-80. PubMed ID: 3322839 [TBL] [Abstract][Full Text] [Related]
10. Open clinical study of Madopar HBS. Ludin HP Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838 [TBL] [Abstract][Full Text] [Related]
11. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations. Quinn NP; Marion MH; Marsden CD Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834 [TBL] [Abstract][Full Text] [Related]
12. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability. Rinne UK Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305 [TBL] [Abstract][Full Text] [Related]
13. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262 [No Abstract] [Full Text] [Related]
14. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease]. Rondot P; Ziegler M; Aymard N; Holzer J Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265 [TBL] [Abstract][Full Text] [Related]
15. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. Lees AJ Eur Neurol; 1987; 27 Suppl 1():126-34. PubMed ID: 3428306 [TBL] [Abstract][Full Text] [Related]
16. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease. Graham JS; Henderson JM; Morris JG; Yiannikas C Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070 [TBL] [Abstract][Full Text] [Related]
17. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic value of Madopar HBS: judgment after 2 years experience. Siegfried J Eur Neurol; 1987; 27 Suppl 1():98-104. PubMed ID: 3428311 [TBL] [Abstract][Full Text] [Related]
19. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations. Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up. Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]